#USA #New York #Securities Class Action #Faruqi & Faruqi #ImmunityBio

Important Announcement for ImmunityBio Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued a crucial reminder for investors in ImmunityBio, Inc. (NASDAQ: IBRX) regarding a significant upcoming deadline related to a federal securities class action lawsuit. This deadline is set for May 26, 2026, and is essential for those who believe they have suffered losses due to the company's actions.

Overview of the Situation

The firm is currently examining potential claims against ImmunityBio following allegations that the company and some of its executives violated federal securities laws. These allegations arise from assertions that misleading statements were made about the company's business operations. Notably, claims include that Patrick Soon-Shiong, a key figure in the company, significantly exaggerated the capabilities of one of ImmunityBio's products, Anktiva. As a result, stakeholders faced detrimental financial consequences when the reality of the company's status became apparent.

On January 23, 2026, ImmunityBio released an update on its clinical trials for Anktiva, specifically related to a combination immunotherapy regimen for glioblastoma patients. This announcement disclosed that critical results regarding median overall survival had not yet been reached, leading to a sharp decline in the company’s stock price by 12.13%, closing at $6.45 per share. This was a clear indicator of the adverse effect that the announcement had on investor confidence.

Class Action Details

In a securities class action, the lead plaintiff is typically the individual or entity with the most significant financial interest in the outcome of the case, who also demonstrates that they share similar interests with the rest of the class members. This person will oversee litigation on behalf of all affected investors. Any investor wishing to be considered for the role of lead plaintiff must act before the May 26 deadline. However, it’s crucial to note that participation as a lead plaintiff does not alter the ability of other class members to recover damages nor impact their decisions on whether to remain involved in the case.

Faruqi & Faruqi encourage all class members, and especially those with further information on ImmunityBio’s practices, including whistleblowers and former employees, to come forward. The legal firm is prepared to offer guidance and assistance to those interested in exploring their rights and options moving forward.

Contact Information

Investors who acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, are urged to reach out to Faruqi & Faruqi for more information. Legal partner Josh Wilson is available for direct consultation at either 877-247-4292 or 212-983-9330 (Ext. 1310). Further details can also be accessed via their official website, www.faruqilaw.com/IBRX.

As time is of the essence, investors should act promptly to ensure their voices are heard in the ongoing legal proceedings that could significantly affect their financial futures.

Conclusion

With the deadline for filing to be a lead plaintiff quickly approaching, it’s a critical time for ImmunityBio investors to strategize their next steps. The financial repercussions of the company's alleged misstatements and misleading practices could be significant, and early action could help mitigate losses. Faruqi & Faruqi remains committed to advocating for the rights of affected investors as the situation continues to evolve.